Effect of Dapagliflozin on Ventricular Arrhythmic Events in Heart Failure Patients With an Implantable Cardioverter Defibrillator
In ICD outpatients with HFrEF, dapagliflozin treatment produces a reduction in arrhythmic ventricular events. This improvement is more evident in patients who have a worse functional class and thus a more precarious hemodynamic state, and in patients who present with significant ventricular reverse remodeling. Therefore, we can hypothesize that the hemodynamic and structural improvements induced by treatment represent, at least in the short-medium term, some of the principal elements justifying the significant reduction in VAb.
Authors
- Luigi Sciarra (ORCID: https://orcid.org/0000-0002-9669-1330)
- Marzia Colopi (ORCID: https://orcid.org/0000-0003-1527-850X)
- Francesca Barba
- Liuba Fusco (ORCID: https://orcid.org/0009-0005-7125-8740)
- Antonio Scarà (ORCID: https://orcid.org/0000-0003-3325-6910)
- Michele Accogli
- Pietro Palmisano (ORCID: https://orcid.org/0000-0001-6705-6218)
- Simonetta Longo
- Martina Nesti (ORCID: https://orcid.org/0000-0001-8995-3884)
- Zefferino Palamà (ORCID: https://orcid.org/0000-0002-9262-6654)
- Simona Minardi
- Giovanni Coluccia (ORCID: https://orcid.org/0000-0003-0292-5202)
- Antonio Gianluca Robles (ORCID: https://orcid.org/0000-0002-2150-3788)
- Silvio Romano (ORCID: https://orcid.org/0000-0003-3520-4786)
- Gabriele De Masi De Luca (ORCID: https://orcid.org/0000-0003-0419-196X)
- Giuseppe De Masi De Luca
Institutions
- University of L'Aquila (IT)
- Ospedale San Carlo (IT)
- Villa Pineta Hospital (IT)
- Ospedale L. Bonomo (IT)
- Govind Ballabh Pant Hospital (IN)
- Fondazione Toscana Gabriele Monasterio (IT)
Publication Details
- Journal
- Cardiology Research
- Published
- 2025-02-28
- DOI
- https://doi.org/10.14740/cr2018
- Citations
- 1
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Università degli Studi dell'Aquila